Applied Dna Sciences Inc (APDN) Has Fallen -5.68%, Becoming A Losing Stock For Investors

Applied Dna Sciences Inc (NASDAQ:APDN) has a beta value of 0.86 and has seen 1.16 million shares traded in the last trading session. The company, currently valued at $1.83M, closed the last trade at $1.66 per share which meant it lost -$0.1 on the day or -5.68% during that session. The APDN stock price is -27610.84% off its 52-week high price of $460.00 and -0.6% below the 52-week low of $1.67. If we look at the company’s 10-day average daily trading volume, we find that it stood at 4.39 million shares traded. The 3-month trading volume is 800.85K shares.

The consensus among analysts is that Applied Dna Sciences Inc (APDN) is Buy stock at the moment, with a recommendation rating of 3.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -3.0.

Applied Dna Sciences Inc (NASDAQ:APDN) trade information

Sporting -5.68% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the APDN stock price touched $1.66 or saw a rise of 26.22%. Year-to-date, Applied Dna Sciences Inc shares have moved -83.73%, while the 5-day performance has seen it change -21.70%. Over the past 30 days, the shares of Applied Dna Sciences Inc (NASDAQ:APDN) have changed -76.57%. Short interest in the company has seen 0.23 million shares shorted with days to cover at 2.06.

Wall Street analysts have a consensus price target for the stock at $1.5, which means that the shares’ value could drop -10.67% from current levels. The projected low price target is $1.5 while the price target rests at a high of $1.5. In that case, then, we find that the current price level is 9.64% off the targeted high while a plunge would see the stock lose 9.64% from current levels.

Applied Dna Sciences Inc (APDN) estimates and forecasts

The company’s shares have lost -96.71% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 53.99%.

1 analysts offering their estimates for the company have set an average revenue estimate of 1.19M for the current quarter. 1 have an estimated revenue figure of 1.28M for the next ending quarter. Year-ago sales stood 929.63k and 797.52k respectively for this quarter and the next, and analysts expect sales will grow by 27.47% for the current quarter and 53.99% for the next.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 60.68% over the past 5 years.

APDN Dividends

Applied Dna Sciences Inc is expected to release its next earnings report on 2025-Feb-12 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.

Applied Dna Sciences Inc (NASDAQ:APDN)’s Major holders

Insiders own 19.47% of the company shares, while shares held by institutions stand at 26.90% with a share float percentage of 33.41%. Investors are also buoyed by the number of investors in a company, with Applied Dna Sciences Inc having a total of 29.0 institutions that hold shares in the company. The top two institutional holders are MATHER GROUP, LLC. with over 700.0 shares worth more than $287.0. As of 2024-06-30, MATHER GROUP, LLC. held 0.0803% of shares outstanding.

Also the top two Mutual Funds that are holding company’s shares are Fidelity Concord Street Trust-Fidelity Extended Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund . As of Jan 31, 2025 , the former fund manager holds about 0.01% shares in the company for having 5.65 shares of worth $9383.0 while later fund manager owns 174.0 shares of worth $288.0 as of Dec 31, 2024 , which makes it owner of about 0.00% of company’s outstanding stock.